Patents by Inventor Janelle Waite

Janelle Waite has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses Thereof
    Publication number: 20230303696
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen- binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: December 7, 2022
    Publication date: September 28, 2023
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos
  • Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof
    Publication number: 20230279113
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: August 17, 2022
    Publication date: September 7, 2023
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos, Alison Crawford
  • Bispecific Anti-PSMA x Anti-CD28 Antibodies and Uses Thereof
    Publication number: 20230272078
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: December 7, 2022
    Publication date: August 31, 2023
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos
  • Bispecific Anti-CD28 X Anti-CD22 Antibodies and Uses Thereof
    Publication number: 20230174652
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: June 21, 2022
    Publication date: June 8, 2023
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Kara Olson, Joyce Wei, George D. Yancopoulos
  • Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof
    Patent number: 11548947
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: January 10, 2023
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos
  • Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
    Patent number: 11453721
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: September 27, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos, Alison Crawford
  • Bispecific anti-CD28 × anti-CD22 antibodies and uses thereof
    Patent number: 11396544
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: July 26, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Kara Olson, Joyce Wei, George D. Yancopoulos
  • BISPECIFIC ANTI-CD28 X ANTI-CD22 ANTIBODIES AND USES THEREOF
    Publication number: 20200239576
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human CD-22. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing CD-22, such as B-cell lymphomas. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: December 18, 2019
    Publication date: July 30, 2020
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Kara Olson, Joyce Wei, George D. Yancopoulos
  • BISPECIFIC ANTI-MUC16 X ANTI-CD28 ANTIBODIES AND USES THEREOF
    Publication number: 20200199233
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16, such as ovarian tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: December 18, 2019
    Publication date: June 25, 2020
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos, Alison Crawford
  • BISPECIFIC ANTI-PSMA X ANTI-CD28 ANTIBODIES AND USES THEREOF
    Publication number: 20190389951
    Abstract: The present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD28, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing PSMA, such as prostate tumors. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an up-regulated or induced targeted immune response is desired and/or therapeutically beneficial.
    Type: Application
    Filed: June 21, 2019
    Publication date: December 26, 2019
    Inventors: Andrew J. Murphy, Dimitris Skokos, Janelle Waite, Erica Ullman, Aynur Hermann, Eric Smith, Lauric Haber, George D. Yancopoulos